Congenital Prosopagnosia, Healthy
Conditions
Keywords
oxytocin, face, memory
Brief summary
The purpose of this study is to determine whether oxytocin affect face perception
Interventions
DRUGOxytocin
Intervention will be examined on control group, and on experimental group as well.
DRUGPlacebo
Placebo will be given to control group and experimental group as well.
Sponsors
Ben-Gurion University of the Negev
Soroka University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* normal or corrected to normal vision
Exclusion criteria
* minors * pregnancy (according to a pregnancy test taken by subjects prior to participation) * a history of asthma or nasal polyps * cardiac disorders * hyponatremia * acute or chronic renal insufficiency * liver cirrhosis * neurological disease * other chronic disease * dementia, or lack of judgment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Memory performance | Day 2 (24 hours after encoding) | At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mood measurement | Day 1 (after oxytocin/placebo uptake) | Participants will fill a PANAS mood questionnaire in order to monitor the effects of mood and fatigue of oxytocin/placebo. We will use ANOVA on the total score of the test in order to verify that differences in performance are not due to change in mood or fatigue after substance uptake. |
Countries
Israel
Outcome results
None listed